DBV Technologies S.A. (NASDAQ:DBVT) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• DBV Technologies S.A. has received an average rating of "Moderate Buy" from brokerages, with one sell rating, three buy ratings, and one strong buy rating among the analysts covering the stock.
• Institutional investors own 71.74% of DBV Technologies's stock, with significant new stakes acquired by firms like Adage Capital Partners and Boxer Capital Management.
• The company reported a loss of $1.55 EPS for the last quarter, significantly missing expectations, but exceeded revenue projections with $1.74 million in sales.

Shares of DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $14.75.

Several brokerages have recently issued reports on DBVT. Wall Street Zen downgraded shares of DBV Technologies from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. The Goldman Sachs Group upgraded shares of DBV Technologies to a "sell" rating and set a $7.25 price objective on the stock in a research note on Thursday, May 29th. Citigroup reiterated an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th. HC Wainwright boosted their price target on shares of DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a report on Monday, May 5th. Finally, JMP Securities reissued a "market outperform" rating and issued a $21.00 price target on shares of DBV Technologies in a report on Thursday, June 26th.

DBV Technologies Price Performance

NASDAQ:DBVT traded up $0.1050 during mid-day trading on Friday, reaching $9.8750. The stock had a trading volume of 12,185 shares, compared to its average volume of 43,942. The business's 50 day moving average is $9.79 and its 200 day moving average is $7.89. DBV Technologies has a fifty-two week low of $2.20 and a fifty-two week high of $12.78. The stock has a market cap of $270.48 million, a P/E ratio of -2.07 and a beta of -0.58.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported ($1.55) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.34). DBV Technologies had a negative net margin of 3,220.49% and a negative return on equity of 287.15%. The company had revenue of $1.74 million for the quarter, compared to analyst estimates of $0.64 million. Equities analysts expect that DBV Technologies will post -7.05 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in DBVT. Nan Fung Trinity HK Ltd. bought a new position in DBV Technologies in the 2nd quarter worth approximately $340,000. Boxer Capital Management LLC bought a new position in DBV Technologies in the 4th quarter worth approximately $154,000. Octagon Capital Advisors LP bought a new position in DBV Technologies in the 2nd quarter worth approximately $9,315,000. MPM Bioimpact LLC bought a new position in DBV Technologies in the 2nd quarter worth approximately $9,649,000. Finally, Adage Capital Partners GP L.L.C. bought a new position in DBV Technologies in the 2nd quarter worth approximately $9,659,000. 71.74% of the stock is owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.